Repeated CBD Administration and Cannabis Outcomes

Summary

This outpatient study examines how cannabidiol (CBD) affects the behavioral and pain-relieving effects of cannabis.

Conditions

• Cannabis
• Abuse Liability
• Experimental Pain in Healthy Human Participants

Interventions

DRUG

Cannabidiol, Medium Dose

Active Cannabidiol: Active cannabidiol (medium dose) will be administered orally for 14 days.

DRUG

Cannabidiol, Higher Dose

Description: Active Cannabidiol: Active cannabidiol (higher dose) will be administered orally for 14 days.

DRUG

Active Inhaled Cannabis

Active Marijuana: Active Marijuana (active inhaled cannabis) will be administered through a vaporizer once per study session day (Day 1, 7, 14) per block (3 blocks total).

DRUG

Placebo Cannabidiol

Inactive/Placebo Cannabidiol: Inactive/placebo cannabidiol will be administered orally for 14 days.

DRUG

Placebo Inhaled Cannabis

Inactive/Placebo Marijuana: Experimental, non-therapeutic administration of an inactive/placebo marijuana dose will be administered through a vaporizer at each study session day (Days 1, 7, 14) per block (3 blocks total).

Sponsors & Collaborators

• National Institute on Drug Abuse (NIDA)

  collaborator NIH

• Hannah Harris

  lead OTHER

Principal Investigators

• Hannah M Harris, Ph.D. · University of Kentucky

Study Design

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

DOUBLE

Model

CROSSOVER

Eligibility

Min Age

18 Years

Max Age

55 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2026-05-31

Primary Completion

2029-12-31

Completion

2029-12-31

FDA Drug

Yes

Countries

• United States

Study Locations